Early Insulin Resistance Panel

Your fasting glucose can look perfectly normal for a decade while your body quietly loses its ability to handle sugar. That is because your pancreas compensates by pumping out more and more insulin, keeping glucose in check through sheer effort. By the time glucose or HbA1c (a measure of average blood sugar over two to three months) finally creeps above the standard cutoff, you may have already accumulated years of metabolic damage to your blood vessels, liver, and organs.

This panel is designed to catch that hidden phase. Instead of relying on glucose alone, it measures insulin output, beta cell health, liver stress, and multiple calculated scores that detect resistance while your standard labs still look clean. The combination matters: no single test in this group tells the full story, but together they reveal whether your metabolism is silently breaking down and how far along the process has gone.

What This Panel Reveals

The tests in this panel cover three overlapping domains: how your body controls blood sugar, how hard your pancreas is working to maintain that control, and whether the metabolic strain is already spilling over into your liver and bloodstream.

Blood Sugar Control: The Late Signal

Glucose and HbA1c are the markers most doctors check first, but they are the last to move. Data from the Whitehall II study, which tracked over 6,500 adults for more than a decade before some developed diabetes, showed that fasting glucose stayed nearly flat until about three years before diagnosis, then rose steeply. Insulin sensitivity, by contrast, had been declining for more than a decade before that glucose spike appeared.

A normal fasting glucose (under 100 mg/dL) and a normal HbA1c (under 5.7%) are reassuring, but they are not the finish line. They tell you your pancreas is still keeping up. They do not tell you how hard it is working to do so.

Insulin Production and Resistance: The Early Signal

This is where the panel earns its name. Fasting insulin, intact insulin (a more precise assay that excludes fragments of proinsulin, the precursor molecule your pancreas converts into active insulin), and C-peptide (a byproduct released in equal amounts every time your pancreas makes insulin) together show both how much insulin your body is producing and whether that production is healthy or compensatory.

When insulin resistance develops, your cells stop responding efficiently to insulin's signal. The pancreas responds by making more. Fasting insulin rises. C-peptide rises in parallel, confirming the pancreas is genuinely secreting more, not just clearing it more slowly. If C-peptide is high alongside high insulin, the picture is clear: your body is overproducing insulin to compensate for resistance.

If C-peptide is low while glucose is rising, the story changes. That pattern suggests your pancreatic beta cells (the cells that manufacture insulin) are starting to fail, a later and more concerning stage. This distinction between "too much demand" and "not enough supply" is something glucose and HbA1c alone cannot make.

Calculated Resistance Scores: Putting Numbers on the Problem

Three calculated indices translate raw lab values into a single resistance estimate. HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) multiplies fasting insulin by fasting glucose and divides by a constant. It was first described in 1985 and has since been validated against the gold standard euglycemic clamp technique in multiple populations. A HOMA-IR above roughly 2.5 is widely used as a threshold suggesting insulin resistance, though optimal cutoffs vary by ethnicity and body composition.

The TyG Index (Triglyceride-Glucose Index) uses fasting triglycerides and glucose instead of insulin. Because triglycerides rise early in insulin resistance (the liver overproduces fat-carrying particles when flooded with insulin), TyG captures a different angle of the same problem. A 2022 meta-analysis pooling data from over 5.7 million participants found that a higher TyG index was associated with a significantly increased risk of cardiovascular events, independent of traditional risk factors.

The CardioIQ Insulin Resistance Score takes a third approach entirely. It uses the size and concentration of lipoprotein particles (measured by nuclear magnetic resonance) to estimate insulin resistance from the lipid side. This score can flag resistance even when fasting glucose, insulin, and triglycerides all appear normal individually, because subtle shifts in particle size occur early in the metabolic cascade.

Liver Stress: The Metabolic Spillover

ALT (alanine aminotransferase) and AST (aspartate aminotransferase) are enzymes that leak into the bloodstream when liver cells are injured. In the context of this panel, they serve as a window into whether insulin resistance has already begun driving fat into the liver, a condition called non-alcoholic fatty liver disease (NAFLD). A meta-analysis published in Diabetes Care found that elevated ALT was associated with approximately a twofold increase in risk of developing type 2 diabetes, even after adjusting for obesity and other metabolic factors.

When ALT is elevated alongside high HOMA-IR and rising triglycerides, the picture is not just insulin resistance in isolation. It is insulin resistance that has already started damaging an organ.

How to Read Your Results Together

The real power of this panel is in the patterns. A single elevated marker might mean nothing. A constellation of shifts across multiple tests tells a clear metabolic story.

When Results Can Be Misleading

Several factors can shift multiple tests in this panel simultaneously. Acute illness, physical trauma, or recent surgery can raise glucose, insulin, ALT, and AST at the same time, mimicking metabolic dysfunction. A single elevated set of results during or shortly after an illness does not mean you are insulin resistant.

Fasting status matters for almost every test here. Eating within 8 to 12 hours of the blood draw can raise glucose, insulin, C-peptide, and triglycerides, inflating HOMA-IR and TyG Index artificially. If your results seem unexpectedly high and you are uncertain about your fasting window, retest with a confirmed 10 to 12 hour fast before drawing conclusions.

Medications also affect interpretation. Corticosteroids raise glucose and insulin. Statins can modestly raise fasting glucose and HbA1c. Metformin lowers all of the metabolic markers in this panel. If you take any of these, your results should be interpreted with that context in mind.

Tracking Over Time

A single set of results gives you a snapshot. Serial testing reveals a trajectory, and trajectory is what predicts outcomes. Someone with a HOMA-IR of 2.0 that was 1.2 a year ago is on a different path than someone with a stable HOMA-IR of 2.0 for three years running.

The Whitehall II data showed that the decline in insulin sensitivity before diabetes diagnosis followed a predictable curve. Catching yourself on that curve early, while interventions like dietary changes, increased physical activity, improved sleep, and weight loss are most effective, is the entire point of this panel. Repeating it every 6 to 12 months lets you see whether your metabolic trajectory is improving, stable, or worsening.

HbA1c is naturally suited to serial tracking because it reflects a two to three month average. But the faster-moving markers (fasting insulin, HOMA-IR, triglycerides) respond to lifestyle changes within weeks, giving you earlier feedback on whether your interventions are working.

What to Do with Your Results

If every marker in this panel is normal, you have strong evidence that your metabolism is functioning well. Retest annually if you have any risk factors for metabolic disease (family history of diabetes, overweight, sedentary lifestyle, history of gestational diabetes, or polycystic ovary syndrome). Retest every two years if you have none.

If HOMA-IR, TyG, or the CardioIQ score is elevated but glucose and HbA1c are still normal, you have caught the problem early. This is the ideal window for intervention. Structured exercise (both aerobic and resistance training), reducing refined carbohydrates and added sugars, improving sleep quality, and losing even 5 to 7% of body weight if overweight can reverse insulin resistance at this stage.

If glucose or HbA1c has started rising, or if C-peptide is declining, schedule a visit with an endocrinologist or a metabolically focused primary care physician. Consider adding a lipid panel and a liver function panel to complete the metabolic picture. If ALT is elevated, an abdominal ultrasound can assess for fatty liver disease.

Do not wait for a diabetes diagnosis to act. Every marker in this panel moves before that threshold is crossed, and every one of them can be pushed back in the right direction with early intervention.